Is the price fair?
What MEDP's price assumes
Medpace Holdings, Inc. trades at 34.7× earnings against 33.6× for the median Diagnostics & Research name, more expensive than its own group.
34.7
Trailing P/E · Diagnostics & Research median 33.6 · 1.03× the median: the market pays up for this one
- Price / sales
- 5.19
Price / sales · as of 2026-Q1
- Free cash flow yield
- 4.8%
Free cash flow yield · Diagnostics & Research median 4.2%
- Growth the price implies
- +6.3%
Growth the price implies · The price pays for +6.3% free cash flow growth a year for a decade; the business has delivered +24% a year over the last three.
Details›
- Price / book2026-Q1
- 23.2
- Healthcare median P/E362 names
- 29.9
- Diagnostics & Research median P/E29 names
- 33.6
- Free cash flow, trailing twelve months
- $707M
- Market capitalisation
- $14.8B
- 3-year revenue growth
- +18%
- 3-year free cash flow growth
- +24%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $504.20 |
| Its own P/E history, median | $537.77 |
| Its own P/E history, upper quartile | $611.76 |
| 52-week range | $393.42 – $620.70 |
| Today | $590.68 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Diagnostics & Research
Ranks #10 of 17 by Smart Score